More recently, several clinical trials demonstrated that PD-1/PD-L1 inhibitors plus chemotherapy and/or antiangiogenic therapy could significantly prolong progression-free and overall survival (PFS and OS) in patients with advanced or metastatic NSCLC [13–15]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.